Jasper Therapeutics, Inc. (JSPR)

Market Cap	47.85M
Revenue (ttm)	n/a
Net Income (ttm)	-91.02M
Shares Out	27.98M
EPS (ttm)	-5.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,132,581
Open	1.850
Previous Close	1.860
Day's Range	1.691 - 1.930
52-Week Range	1.390 - 23.890
Beta	3.06
Analysts	Buy
Price Target	25.60 (+1,397.08%)
Earnings Date	Nov 10, 2025

About JSPR

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 64
• Stock Exchange: NASDAQ
• Ticker Symbol: JSPR
• Website: https://jaspertx.com

Analyst Forecast

According to 12 analysts, the average rating for JSPR stock is "Buy." The 12-month stock price target is $25.6, which is an increase of 1,397.08% from the latest price.

Price Target

$25.6

(1,397.08% upside)

Analyst Consensus: Buy